| Unique ID issued by UMIN | UMIN000059821 |
|---|---|
| Receipt number | R000068376 |
| Scientific Title | Treatment of postoperative nausea and vomiting (PONV) after prophylactic administration of ondansetron in oral surgery |
| Date of disclosure of the study information | 2025/11/25 |
| Last modified on | 2025/11/19 10:01:47 |
Treatment of postoperative nausea and vomiting (PONV) after prophylactic administration of ondansetron in oral surgery
Treatment of postoperative nausea and vomiting (PONV) after prophylactic administration of ondansetron in oral surgery
Treatment of postoperative nausea and vomiting (PONV) after prophylactic administration of ondansetron in oral surgery
Treatment of postoperative nausea and vomiting (PONV) after prophylactic administration of ondansetron in oral surgery
| Japan |
jaw deformity
| Dental medicine |
Others
NO
To address the optimal treatment for patients who develop PONV after prophylactic administration of ondansetron during oral surgery under general anesthesia.
Efficacy
Improvement rate of PONV 15 minutes after administration of therapeutic drugs(study drug I) for PONV occurring despite prophylactic ondansetron administration
Patient background (age, sex, height, weight, smoking history, and presence or absence of motion sickness/ PONV)
surgical and anesthetic factors (operation name, operation time, anesthesia time, total infusion volume, blood loss, intraoperative opioid use, and postoperative opioid use)
Improvement rate of PONV 15 minutes after administration of the investigational drug (Study Drug II) for PONV that occurred after administration of Study Drug I
Degree of PONV (change in NRS 15 minutes after administration of study drug I and II, presence or absence of vomiting up to 24 hours after the end of anesthesia)
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Active
2
Treatment
| Medicine |
In the ondansetron group, patients who develop PONV after prophylactic administration of ondansetron receive an additional 4 mg of ondansetron. If PONV does not improve, 10 mg of metoclopramide is administered.
In the metoclopramide group, patients who develop PONV after prophylactic administration of ondansetron receive 10 mg of metoclopramide. If PONV does not improve, 4 mg of ondansetron is administered.
| 20 | years-old | <= |
| 50 | years-old | >= |
Male and Female
Patients undergoing orthognathic surgery
ASA-PS 1-2
Patient who gave consent for this study
<20 or >50 years of age, ASA-PS 3 or higher, patient who did not give consent for this study,use of antiemetics within 24 h before surgery, contraindicated for administration of medications used in this study, emergency surgery
70
| 1st name | kyotarou |
| Middle name | |
| Last name | koshika |
Tokyo Dental College
Dental Anesthesiology
101-0061
2-9-18 Misakicyo,Chiyodaku,Tokyo-to 101-0061 Japan
03-6380-9001
koshikakyotarou@tdc.ac.jp
| 1st name | hidetoshi |
| Middle name | |
| Last name | kanawa |
Tokyo Dental College
Dental Anesthesiology
101-0061
2-9-18 Misakicyo,Chiyodaku,Tokyo-to 101-0061 Japan
03-6380-9001
kanawahidetoshi@tdc.ac.jp
Tokyo Dental College
self funding
Self funding
Tokyo Dental College Ethics Review Board
2-9-18 Misakicyo,Chiyodaku,Tokyo-to 101-0061 Japan
03-6380-9001
drinri@tdc.ac.jp
NO
| 2025 | Year | 11 | Month | 25 | Day |
Unpublished
Preinitiation
| 2025 | Year | 11 | Month | 07 | Day |
| 2025 | Year | 11 | Month | 07 | Day |
| 2025 | Year | 11 | Month | 25 | Day |
| 2028 | Year | 03 | Month | 31 | Day |
| 2025 | Year | 11 | Month | 19 | Day |
| 2025 | Year | 11 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068376